Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,854 shares of the medical equipment provider’s stock after selling 1,501 shares during the period. Mutual of America Capital Management LLC’s holdings in Hologic were worth $2,347,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic in the fourth quarter worth $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic in the third quarter worth $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic in the third quarter worth $33,000. Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Hologic in the fourth quarter worth $33,000. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Hologic by 42.2% in the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 155 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 in the last ninety days. Corporate insiders own 1.75% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $75.38 on Friday. The firm has a market cap of $17.69 billion, a P/E ratio of 35.73, a P/E/G ratio of 2.54 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88. The firm has a fifty day moving average of $75.75 and a two-hundred day moving average of $72.54.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period last year, the business earned $1.07 EPS. As a group, research analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of several recent research reports. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Raymond James raised their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. UBS Group raised their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Evercore ISI raised their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.